Application Value of CK5/6 Combined with GATA-3 in Diagnosis of Breast Cancer

Abstract

Background: This study explores the application value of CK5/6 combined with GATA-3 in diagnosis of breast cancer. Methods: The clinical data of 86 patients with suspected breast cancer admitted to our hospital from August 2022 to May 2023 were retrospectively analyzed. 51 patients with breast cancer confirmed byathological examination were assigned to the breast cancer group, and 35 patients with benign breast lesions were assigned to the benign group. The positive detection rates of CK5/6 and GATA-3 were collected, and the diagnostic results of CK5/6 combined with GATA-3 as well as pathological examination were compared. The diagnostic value of CK5/6 combined with GATA-3 in breast cancer was analyzed by the area under the curve (AUC) for receiver operating characteristic (ROC). Results: The positive rates of CK5/6 and GATA-3 in breast cancer group were significantly higher than those in benign group (p < 0.05). The co-detection of CK5/6 and GATA-3 were positive in 41 cases, and negative in 45 cases. Among the gold standard (pathological diagnosis) diagnostic results, 51 cases were positive and 35 cases were negative. The concordance index between combined diagnosis and gold standard diagnosis was 0.631. Conclusion: CK5/6 combined with GATA-3 may have a good diagnostic value for breast cancer, which can be used as the secondary indicator for the early diagnosis of breast cancer.